Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in sost-deficient mice

Endocrinology

Volumn 152, Issue 8, 2011, Pages 2963-2975

  Robling, Alexander G ^a,b   Kedlaya, Rajendra ^a   Ellis, Shana N ^a   Childress, Paul J ^a   Bidwell, Joseph P ^a   Bellido, Teresita ^a   Turner, Charles H ^b  

^a INDIANA UNIVERSITY   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE MASS; CATABOLISM; CONTINUOUS INFUSION; CORTICAL BONE; DOSE RESPONSE; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; HUMAN; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SOST GENE; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; COLLAGEN TYPE I; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MICE; PEPTIDE FRAGMENTS; PEPTIDES; TERIPARATIDE;

EID: 79960746000     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0049     Document Type: Article

References (55)

1. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
2. Stroup JS, Rivers SM, Abu-Baker AM, Kane MP 2007 Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 27:779-788
3. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535 (Pubitemid 35247036)
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
5. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE 1994 Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723 (Pubitemid 24332666)
6. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK 2008 Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806-818
7. Yu S, Franceschi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Patrene K, Hankenson K, Roodman GD, Xiao G 2009 Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One 4:e7583
8. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC 2009 Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44:275-286
9. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638
10. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL 2003 Proteasomal degradation of Runx2 shortens parathyroid hormone-induced antiapoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272 (Pubitemid 37548867)
11. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446 (Pubitemid 29534328)
12. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC 2010 Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res 25:2427-2437
13. Liu F, Lee SK, Adams DJ, Gronowicz GA, Kream BE 2007 CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone 40:1135-1143 (Pubitemid 46394619)
14. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK 2002 Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143:4038-4047 (Pubitemid 35244383)
15. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK 2005 Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596 (Pubitemid 41446596)
16. Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T, Hurley MM 2009 Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 219:143-151
17. Wang Y, Nishida S, Boudignon BM, Burghardt A, Elalieh HZ, Hamilton MM, Majumdar S, Halloran BP, Clemens TL, Bikle DD 2007 IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 22:1329-1337 (Pubitemid 351339678)
18. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE 2005 Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95:1178-1190 (Pubitemid 41420125)
19. Li X, Liu H, Qin L, Tamasi J, Bergenstock M, Shapses S, Feyen JH, Notterman DA, Partridge NC 2007 Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 282:33086-33097 (Pubitemid 350159330)
20. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497
21. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH 2006 The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698-23711
22. Iwaniec UT, Wronski TJ, Liu J, Rivera MF, Arzaga RR, Hansen G, Brommage R 2007 PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 22:394-402 (Pubitemid 46797122)
23. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X 2008 Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22:2968-2979
24. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC 2000 An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535-538
25. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583 (Pubitemid 41446595)
26. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158 (Pubitemid 40962421)
27. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA 2010 Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-1997
28. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
29. Kramer I, Loots GG, Studer A, Keller H, Kneisse lM 2010 Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189
30. Barry K, Tulum I, Monasterios R, Velasquez R, Manoharan R, Kobayashi T, Harris S, Bouxsein M, Feng J, Bringhurst F, Pajevic Divieti P 2009 Mice lacking PTH receptors in osteocytes failed to respond to intermittent administration of PTH. J Bone Miner Res 24(Suppl 1):S12
31. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844 (Pubitemid 41598769)
32. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW 2005 SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327
33. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869 (Pubitemid 351768804)
34. Niziolek PJ, Murthy S, Ellis SN, Sukhija KB, Hornberger TA, Turner CH, Robling AG 2009 Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. J Cell Physiol 221:579-585
35. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA 2010 Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46:1486-1497
36. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringhurst FR, Kronenberg HM 2010 Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11:161-171
37. Yao GQ, Wu JJ, Troiano N, Insogna K 2011 Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29:141-148
38. Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE 2010 Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 25:190-199
39. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS 2007 Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 210:352-357 (Pubitemid 44956880)
40. Romero G, Sneddon WB, Yang Y, Wheeler D, Blair HC, Friedman PA 2010 Parathyroid hormone receptor directly interacts with dishevelled to regulate β-catenin signaling and osteoclastogenesis. J Biol Chem 285:14756-14763
41. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276 (Pubitemid 37522584)
42. Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, Latham JA 2004 Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 279:36293-36298 (Pubitemid 39128966)
43. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R 2006 Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749
44. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
45. Lu W, Liu CC, Thottassery JV, Bu G, Li Y 2010 Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/β-catenin signaling in cancer cells. Biochemistry 49:4635-4643
46. Semënov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775 (Pubitemid 41040710)
47. Choi HY, Dieckmann M, Herz J, Niemeier A 2009 Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 4:e7930
48. Leupin O, Halleux C, Morvan F, Hu S-I, Lu C, Bauer A, Kneissel M 2009 LRP4 is a novel osteoblast and osteocyte expressed specific facilitator of SOST-mediated inhibition of in vitro bone formation. J Bone Miner Res 24(Suppl 1):S77
49. Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R 2010 Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun 392:36-40
50. Craig TA, Kumar R 2010 Sclerostin-erbB3 interactions: Modulation of erbB3 activity by sclerostin. Biochem Biophys Res Commun 402:421-424
51. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446 (Pubitemid 46756429)
52. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875
53. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 24:1651-1661
54. Tian X, Jee WS, Li X, Paszty C, Ke HZ 2011 Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48:197-201
55. Brommage R, Liu J, Suwanichkul A, Powell DR 2006 High bone mass in sclerostin-deficient knockout mice. J Musculoskelet Neuronal Interact 6:392